B

BioLine RX Ltd
TASE:BLRX

Watchlist Manager
BioLine RX Ltd
TASE:BLRX
Watchlist
Price: 2.4 ILS -4% Market Closed
Market Cap: 55m ILS

EV/EBIT
Enterprise Value to EBIT

0.1
Current
-2.6
Median
5.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
0.1
=
Enterprise Value
-5.1m ILS
/
EBIT
-18m USD
EBIT Growth EV/EBIT to Growth
IL
B
BioLine RX Ltd
TASE:BLRX
Average EV/EBIT: 17.6
0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 158.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
23.6
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.6 N/A N/A
AU
CSL Ltd
ASX:CSL
23
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.1
11%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -434.3 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A